Correction to: BMC Health Serv Res

https://doi.org/10.1186/s12913-019-4680-2

In the original publication of this article [1], there is a mistake in the Fig. 2a, b, and c. The mistake is in the very last column where it shows TOTAL. The updated Fig. 2 is shown below. Additionally, a footnote “Total is based on the average discounted price amongst all provinces.” should be added to Table 2 and Additional files 1, 2, and 3.

Fig. 2
figure 1

a. Overall units purchased of insulin glargine by province. All dollar figures are in Canadian dollars. BC=British Columbia, AB = Alberta, SK=Saskatchewan, MB = Manitoba, ON=Ontario, QC = Quebec, NB=New Brunswick, NS=Nova Scotia, PEI/NL = Prince Edward Island / Newfoundland. Potential Savings represents the potential savings that could have been realized if the biosimilar drug Basaglar® were purchased instead of the originator drug Lantus®. b Overall units purchased of filgrastim by province. All dollar figures are in Canadian dollars. BC=British Columbia, AB = Alberta, SK=Saskatchewan, MB = Manitoba, ON=Ontario, QC = Quebec, NB=New Brunswick, NS=Nova Scotia, PEI/NL = Prince Edward Island / Newfoundland. Potential Savings represents the potential savings that could have been realized if the biosimilar drug Grastofil® were purchased instead of the originator drug Neupogen®. c Overall units purchased of infliximab by province. All dollar figures are in Canadian dollars. BC=British Columbia, AB = Alberta, SK=Saskatchewan, MB = Manitoba, ON=Ontario, QC = Quebec, NB=New Brunswick, NS=Nova Scotia, PEI/NL = Prince Edward Island / Newfoundland. Potential Savings represents the potential savings that could have been realized if the biosimilar drug Inflectra® were purchased instead of the originator drug Remicade®

Full size image
Table 2 Realized and Unrealized Savings for the biosimilars Basaglar®, Grastofil®, and Inflectra® Relative to Captured Market Share by Province
Full size table